Earnings, buyback and dividend set the stage for Healthcare Realty Trust

Healthcare Realty Trust (HR) reported first quarter 2026 results, showing lower revenue than a year earlier alongside a much smaller net loss, while also completing a share repurchase tranche and affirming its quarterly dividend.

The recent 13.1% 30 day share price return and 18.1% 90 day share price return suggest momentum has picked up, while the 1 year total shareholder return of 38.7% contrasts with a weaker 5 year record.

If Healthcare Realty Trust's mix of income and capital returns has your attention, this could be a good moment to see what else stands out among solid balance sheet and fundamentals stocks screener (44 results)

With a recent 1 year total return of 38.7%, a value score of 3 and an estimated 34% intrinsic discount, is Healthcare Realty Trust still trading below what its fundamentals suggest, or is the market already pricing in future growth?

Most Popular Narrative: 4.2% Overvalued

Healthcare Realty Trust last closed at $19.99, compared with the most followed fair value estimate of $19.18. This suggests a finely balanced picture rather than a deep-value setup.

Balance sheet strengthening via significant asset dispositions (focused on non-core, low-growth properties), targeted deleveraging, and a right-sized dividend increases financial flexibility for reinvestment, positioning the company for improved net margins, earnings quality, and greater capital deployment into high-return projects.

Curious what kind of revenue path, margin shift, and earnings profile sit behind that fair value and premium multiple story? The detailed narrative lays out a very specific glide path for rental income, profitability, and capital recycling that is far from conservative, with a forward earnings multiple that stands out even within health care REITs.

Result: Fair Value of $19.18 (OVERVALUED)

However, it is worth keeping in mind that a slower lease up in key properties or higher-than-expected borrowing costs could quickly challenge the current fair value story.

Another Way To Look At HR's Valuation

The analyst narrative leans on earnings forecasts and a rich future P/E, but the SWS DCF model comes back with an estimated future cash flow value of $30.11 per share, versus the current $19.99 price. That gap suggests investors are being asked to choose between a growth story and a cash flow story. Which one feels more convincing to you?

Next Steps

With that mixed picture in mind, the key question is how you weigh the upside against the concerns. Move quickly, review the latest data, and weigh the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If HR has sharpened your focus, do not stop here. The broader market holds plenty of other stocks that could better match your goals and risk comfort.

• Target dependable income by reviewing stocks described as dividend fortresses with yields above 5% through the 12 dividend fortresses.
• Hunt for potential mispricing by scanning companies that combine quality fundamentals with attractive pricing using the 51 high quality undervalued stocks.
• Dial back portfolio risk by focusing on stocks that show resilient fundamentals and lower risk scores via the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.